Get the Stockscreener App
0.3702
2.58%
-0.0098
Athira Pharma Inc stock is traded at $0.3702, with a volume of 348.70K.
It is down -2.58% in the last 24 hours and up +23.40% over the past month.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.
See More
Previous Close:
$0.38
Open:
$0.34
24h Volume:
348.70K
Relative Volume:
0.65
Market Cap:
$14.45M
Revenue:
-
Net Income/Loss:
$-117.67M
P/E Ratio:
-0.1198
EPS:
-3.09
Net Cash Flow:
$-101.06M
1W Performance:
-19.17%
1M Performance:
+23.40%
6M Performance:
-29.53%
1Y Performance:
-88.61%
1-Day Range:
$0.3236
$0.3784
1-Week Range:
$0.3236
$0.4494
52-Week Range:
$0.2195
$3.67
Athira Pharma Inc Stock (ATHA) Company Profile
Name
Athira Pharma Inc
Sector
Industry
Phone
(425) 620-8501
Address
18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL
Compare ATHA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATHA
Athira Pharma Inc
|
0.3702 | 14.84M | 0 | -117.67M | -101.06M | -3.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Athira Pharma Inc Stock (ATHA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-19-24 | Downgrade | Mizuho | Outperform → Neutral |
| Sep-04-24 | Downgrade | BTIG Research | Buy → Neutral |
| Sep-04-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Sep-04-24 | Downgrade | Rodman & Renshaw | Buy → Neutral |
| Aug-19-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-17-22 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Jul-07-22 | Initiated | Mizuho | Buy |
| Jun-23-22 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jun-23-22 | Downgrade | Jefferies | Buy → Hold |
| Jun-23-22 | Downgrade | Stifel | Buy → Hold |
| May-10-22 | Initiated | BTIG Research | Buy |
| Apr-21-22 | Initiated | Berenberg | Buy |
| Dec-15-21 | Initiated | Goldman | Neutral |
| Oct-13-20 | Initiated | Goldman | Buy |
| Oct-13-20 | Initiated | JMP Securities | Mkt Outperform |
| Oct-13-20 | Initiated | Jefferies | Buy |
| Oct-13-20 | Initiated | Stifel | Buy |
View All
Athira Pharma Inc Stock (ATHA) Latest News
Using fundamentals and technicals on Athira Pharma Inc.Momentum Stocks with Breakout Potential - Newser
When is Athira Pharma Inc. stock expected to show significant growthTop Growth Tips For Fast Growth - jammulinksnews.com
What markets is PYPD expanding into Is Athira Pharma Inc. stock a good long term investment option - jammulinksnews.com
How volatile is Athira Pharma Inc. stock compared to the marketMarket Forecast Planner To Watch Now - jammulinksnews.com
How Athira Pharma Inc. stock performs during market volatilityFree AI-Powered Trade Planning with Indicators - Newser
Can technical indicators confirm Athira Pharma Inc.’s reversalWeekly Portfolio Update with ROI Focus - Newser
Visual trend scoring systems applied to Athira Pharma Inc.Long-Term Safety Investment Analysis Report - Newser
Will Athira Pharma Inc. bounce back from current supportMomentum Stocks with Breakout Potential - Newser
What institutional investors are buying Athira Pharma Inc. stockBeginner Investor Alerts For Fast Growth - jammulinksnews.com
Why is Athira Pharma Inc. stock attracting strong analyst attentionRetirement Planning Review With Proven Results - jammulinksnews.com
Does Athira Pharma Inc. stock perform well during market downturnsWealth Building Insights With Low Risk - jammulinksnews.com
What are analysts’ price targets for Athira Pharma Inc. in the next 12 monthsTop Growth Strategy From AI Tools - jammulinksnews.com
What MACD signals say about Athira Pharma Inc.Free Buy Low Sell High Stock Watch - Newser
RSI Crosses Above 30 for Athira Pharma Inc. — Reversal in SightEarly Breakout Entry Point Notifications Sent - metal.it
New Product Launches: Will They Boost Athira Pharma Inc. Stock in 2025Breakout Momentum Picks With Protection Outlined - metal.it
Published on: 2025-07-29 23:41:45 - metal.it
Will Athira Pharma Inc. Stock Benefit from AI and Green Energy TrendsDaily Growth Stock Pick Reports Show Bullish Signals - metal.it
Is Now a Good Time to Reenter Athira Pharma Inc.Swing Setup With Technical Confirmation Explained - metal.it
Athira Pharma Inc. Recovery Linked to Earnings SurpriseFast Gaining Stock Screener Reports Released - metal.it
Sector ETF performance correlation with Athira Pharma Inc.Free Short Term Buy List With Stop Protection - Newser
Why Athira Pharma Inc. stock attracts strong analyst attentionSummary of Trade Cycles in 5-Year Range - Newser
Is Athira Pharma Inc. stock overvalued or undervaluedExpert Picks Forecasts Backed By Experts - jammulinksnews.com
How does Athira Pharma Inc. generate profit in a changing economyAchieve breakthrough performance with smart picks - jammulinksnews.com
What are Athira Pharma Inc. company’s key revenue driversCapitalize on momentum-driven investment opportunities - jammulinksnews.com
Reversal indicators forming on Athira Pharma Inc. stockShort-Term Profit Alert With Entry Forecast - Newser
Is it the right time to buy Athira Pharma Inc. stockGet daily expert analysis for smarter investing - jammulinksnews.com
Sector ETF performance correlation with Athira Pharma Inc. Smart Stock Forecast Using AI Algorithms - Newser
What are the latest earnings results for Athira Pharma Inc.Get real-time updates on market trends - jammulinksnews.com
Athira Pharma Inc. Earnings Report Breakdown: What Investors Should KnowFree Investment Community - metal.it
What is Athira Pharma Inc. company’s growth strategyInvest confidently with expert support - jammulinksnews.com
What makes Athira Pharma Inc. stock price move sharplyUnlock exclusive investment alerts - jammulinksnews.com
Published on: 2025-07-27 20:04:45 - jammulinksnews.com
Buy Signal for Athira Pharma Inc. Stock Key Technical Indicators to WatchFree Stock Market Return Analysis - Newser
Is Athira Pharma Inc. a good long term investmentMarket-crushing profits - PrintWeekIndia
Athira Pharma Inc. Stock Analysis and ForecastUnprecedented profits - Autocar Professional
What drives Athira Pharma Inc. stock priceHigh-yield capital appreciation - jammulinksnews.com
What analysts say about Athira Pharma Inc. stockSkyrocketing investment returns - jammulinksnews.com
Athira Pharma (NASDAQ:ATHA) Trading Up 8.4% – Here’s Why - Defense World
Athira Pharma Inc Stock (ATHA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Athira Pharma Inc Stock (ATHA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| CHURCH KEVIN | CHIEF SCIENTIFIC OFFICER |
Jul 01 '25 |
Sale |
0.29 |
8,526 |
2,502 |
168,901 |
| Litton Mark James | President and CEO |
Jun 30 '25 |
Option Exercise |
0.00 |
108,334 |
0 |
350,925 |
| Litton Mark James | President and CEO |
Jul 01 '25 |
Sale |
0.29 |
25,123 |
7,374 |
325,802 |
| San Martin Javier | CHIEF MEDICAL OFFICER |
Jun 30 '25 |
Option Exercise |
0.00 |
46,666 |
0 |
82,507 |
| San Martin Javier | CHIEF MEDICAL OFFICER |
Jul 01 '25 |
Sale |
0.29 |
10,842 |
3,182 |
71,665 |
| Worthington Mark | General Counsel and CCO |
Jun 30 '25 |
Option Exercise |
0.00 |
36,666 |
0 |
120,401 |
| Worthington Mark | General Counsel and CCO |
Jul 01 '25 |
Sale |
0.29 |
8,526 |
2,502 |
111,875 |
| Renninger Robert | SVP, Finance and Accounting |
Jun 30 '25 |
Option Exercise |
0.00 |
12,359 |
0 |
112,083 |
| Renninger Robert | SVP, Finance and Accounting |
Jul 01 '25 |
Sale |
0.29 |
2,897 |
850 |
109,186 |
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):